Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK0928-040 | |||
| 2005_106 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK0928, gaboxadol / Duration of Treatment 3 Weeks | Drug | |||
| Placebo / Duration of Treatment 3 Weeks | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Patient-reported total sleep time. |
| Measure | Description | Time Frame |
|---|---|---|
| Patient-reported time to sleep onset, number of awakenings, wake time after sleep onset and premature awakening. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| ID | Term |
|---|---|
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C015542 | gaboxadol |
| D000081206 | Duration of Therapy |
| ID | Term |
|---|---|
| D005791 | Patient Care |
| D013812 | Therapeutics |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D001523 |
| Mental Disorders |